Royal Bank of Canada
ZVSA

Royal Bank of Canada’s ZyVersa Therapeutics ZVSA Stock Holding History

Royal Bank of Canada’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-52
Closed – – 7320
2024
Q3 		$0 Buy
+52
New +$167 ﹤0.01% 7558

Other funds holding ZVSA

Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada's ZVSA Position: Q4 2024 in Review

Royal Bank of Canada sold out of ZyVersa Therapeutics (ZVSA) in Q4 2024, closing a stake of 52 shares.

Royal Bank of Canada first reported a position in ZVSA in Q3 2024 and held it in 1 quarter. The position peaked at $0 in Q3 2024. 8 funds tracked by Wall St. Rank hold ZVSA as of Q4 2024.

  • Royal Bank of Canada reported no remaining ZyVersa Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 52 ZyVersa Therapeutics shares in Q4 2024.
  • Royal Bank of Canada first reported a position in ZyVersa Therapeutics in Q3 2024 and held it in 1 quarter.
  • Royal Bank of Canada's ZyVersa Therapeutics position peaked at $0 in Q3 2024.
  • 8 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2024.

Based on Royal Bank of Canada's 13F filing for Q4 2024, filed 14 Feb 2025.